Search Within

Thoracic Oncology

  1. "Lu Wang"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (17)
Groups
  1. Department of Medicine (37)
  2. Department of Pathology and Laboratory Medicine (37)
  3. Solid Tumor Oncology Division (37)
  4. GSK Faculty (36)
  5. Human Oncology and Pathogenesis Program (36)
  6. Tow Center for Developmental Oncology (TCDO) (36)

More Groups

People
  1. Lu Wang (37)
  2. Marc Ladanyi (35)
  3. Mark Kris (25)
  4. Alexander Drilon (16)
  5. Gregory Riely (16)
  6. Natasha Rekhtman (15)

More People

Years
  1. 2025 (1)
  2. 2019 (1)
  3. 2018 (1)
  4. 2017 (2)
  5. 2016 (5)
  6. 2015 (6)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. Journal of Thoracic Oncology (7)
  3. Annals of Oncology (3)
  4. Cancer Discovery (3)
  5. Clinical Cancer Research (3)
  6. Proceedings of the National Academy of Sciences of the United States of America (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (8)
  2. Elsevier Inc. (8)
  3. American Association for Cancer Research (7)
  4. Elsevier Science, Inc. (3)
  5. National Academy of Sciences (3)
  6. Oxford University Press (3)

More Publishers

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chromothripsis-mediated small cell lung carcinoma
    Journal Article

    Rekhtman, N.; Tischfield, S. E.; Febres-Aldana, C. A.; Lee, J. J. K.; Chang, J. C.; Herzberg, B. O.; Selenica, P.; Woo, H. J.; Vanderbilt, C. M.; Yang, S. R.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement
    Journal Article

    Dogan, S.; Ng, C. K. Y.; Xu, B.; Kumar, R.; Wang, L.; Edelweiss, M.; Scott, S. N.; Zehir, A.; Drilon, A.; Morris, L. G. T.; more...
    Human Pathology (2019)

    Fulltext@MSK | Save
  • YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Journal Article

    Fan, P. D.; Narzisi, G.; Jayaprakash, A. D.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Yu, H. A.; Jordan, E. J.; Paik, P. K.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Journal Article

    Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases
    Journal Article

    Paik, P. K.; Shen, R.; Won, H.; Rekhtman, N.; Wang, L.; Sima, C. S.; Arora, A.; Seshan, V.; Ladanyi, M.; Berger, M. F.; more...
    Cancer Discovery (2016)

    Fulltext@MSK | Save
  • Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
    Journal Article

    Drilon, A.; Bergagnini, I.; Delasos, L.; Sabari, J.; Woo, K. M.; Plodkowski, A.; Wang, L.; Hellmann, M. D.; Joubert, P.; Sima, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer
    Journal Article

    Drilon, A.; Somwar, R.; Wagner, J. P.; Vellore, N. A.; Eide, C. A.; Zabriskie, M. S.; Arcila, M. E.; Hechtman, J. F.; Wang, L.; Smith, R. S.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save